Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Drugging MYCN oncogenic signalling through the MYCN-PA2G4 binding interface.

Koach J, Holien JK, Massudi H, Carter DR, Ciampa OC, Herath M, Lim T, Seneviratne JA, Milazzo G, Murray JE, McCarroll JA, Liu B, Mayoh C, Keenan B, Stevenson BW, Gorman MA, Bell JL, Doughty L, H├╝ttelmaier S, Oberthuer A, Fischer M, Gifford AJ, Liu T, Zhang X, Zhu S, Gustafson WC, Haber M, Norris MD, Fletcher JI, Perini G, Parker MW, Cheung BB, Marshall GM.

Cancer Res. 2019 Sep 9. pii: canres.1112.2019. doi: 10.1158/0008-5472.CAN-19-1112. [Epub ahead of print]

PMID:
31501192
2.

Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis.

Sutton SK, Cheung BB, Massudi H, Tan O, Koach J, Mayoh C, Carter DR, Marshall GM.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2241-2250. doi: 10.1007/s00432-019-02981-5. Epub 2019 Jul 24.

3.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

4.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

5.

Thymosin-╬▓4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Cheung BB, Tan O, Koach J, Liu B, Shum MS, Carter DR, Sutton S, Po'uha ST, Chesler L, Haber M, Norris MD, Kavallaris M, Liu T, O'Neill GM, Marshall GM.

Mol Oncol. 2015 Aug;9(7):1484-500. doi: 10.1016/j.molonc.2015.04.005. Epub 2015 Apr 29.

6.

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells.

Sutton SK, Koach J, Tan O, Liu B, Carter DR, Wilmott JS, Yosufi B, Haydu LE, Mann GJ, Thompson JF, Long GV, Liu T, McArthur G, Zhang XD, Scolyer RA, Cheung BB, Marshall GM.

Oncotarget. 2014 Oct 30;5(20):10127-39.

7.

The histone deacetylase SIRT2 stabilizes Myc oncoproteins.

Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, Liu T.

Cell Death Differ. 2013 Mar;20(3):503-14. doi: 10.1038/cdd.2012.147. Epub 2012 Nov 23.

8.

Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy.

Gardner CR, Cheung BB, Koach J, Black DS, Marshall GM, Kumar N.

Bioorg Med Chem. 2012 Dec 1;20(23):6877-84. doi: 10.1016/j.bmc.2012.09.035. Epub 2012 Oct 3.

PMID:
23088909
9.

TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members.

Bell JL, Malyukova A, Holien JK, Koach J, Parker MW, Kavallaris M, Marshall GM, Cheung BB.

PLoS One. 2012;7(5):e37470. doi: 10.1371/journal.pone.0037470. Epub 2012 May 21.

10.

The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro.

Cheung BB, Koach J, Tan O, Kim P, Bell JL, D'andreti C, Sutton S, Malyukova A, Sekyere E, Norris M, Haber M, Kavallaris M, Cunningham AM, Proby C, Leigh I, Wilmott JS, Cooper CL, Halliday GM, Scolyer RA, Marshall GM.

J Pathol. 2012 Feb;226(3):451-62. doi: 10.1002/path.2986. Epub 2011 Oct 18.

11.

TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells.

Marshall GM, Bell JL, Koach J, Tan O, Kim P, Malyukova A, Thomas W, Sekyere EO, Liu T, Cunningham AM, Tobias V, Norris MD, Haber M, Kavallaris M, Cheung BB.

Oncogene. 2010 Nov 18;29(46):6172-83. doi: 10.1038/onc.2010.340. Epub 2010 Aug 23.

12.

Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.

Thomas WD, Chen J, Gao YR, Cheung B, Koach J, Sekyere E, Norris MD, Haber M, Ellis T, Wainwright B, Marshall GM.

Oncogene. 2009 Apr 2;28(13):1605-15. doi: 10.1038/onc.2009.3. Epub 2009 Feb 23.

PMID:
19234491
13.

The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation.

Raif A, Marshall GM, Bell JL, Koach J, Tan O, D'andreti C, Thomas W, Sekyere E, Norris M, Haber M, Kavallaris M, Cheung BB.

Cancer Lett. 2009 May 8;277(1):82-90. doi: 10.1016/j.canlet.2008.11.030. Epub 2009 Jan 14.

PMID:
19147277
14.

ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells.

Bohlken A, Cheung BB, Bell JL, Koach J, Smith S, Sekyere E, Thomas W, Norris M, Haber M, Lovejoy DB, Richardson DR, Marshall GM.

Br J Cancer. 2009 Jan 13;100(1):96-105. doi: 10.1038/sj.bjc.6604833.

15.

Differences of gene expression in bovine alveolar macrophages infected with virulent and attenuated isogenic strains of Mycobacterium bovis.

Wedlock DN, Kawakami RP, Koach J, Buddle BM, Collins DM.

Int Immunopharmacol. 2006 Jun;6(6):957-61. Epub 2006 Jan 31.

PMID:
16644481
16.

Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.

Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM, Hewinson RG, van Drunen Littel-van den Hurk S, Babiuk LA, Hecker R, Buddle BM.

Infect Immun. 2005 Jun;73(6):3540-6.

Supplemental Content

Support Center